“South Korea will temporarily suspend providing AstraZeneca’s COVID-19 vaccine to people below 60 amid a European review,” the message said.
It is mentioned that the EMA should announce the results of the study whether or not some cases of blood clotting of adults are tied with the AstraZeneca vaccine.
Meanwhile, South Korea’s food and drug safety ministry stated that it provided the final agreement for the Johnson & Johnson vaccine after the group of experts defined that a single shot was safe and effective.
On April 6, the EMA representative confirmed there is a connection between the AstraZeneca vaccine against coronavirus and the development of blood clots in the patients' bodies.
The first messages about side effects after vaccination with AstraZeneca (Vaxzevria) appeared in early March. Austria was the first to state it suspends the vaccination with the use of this drug. Later, more than 20 countries did the same.